TABLE 2.
Outcomes after liver transplantation (n = 93 patients)
| Event | n (%) or median (IQR) |
|---|---|
| Post‐reperfusion syndrome a | 11 (12%) |
| Serum lactate—mmol/L | |
| Peak lactate after reperfusion | 4.5 (2.9–6.4) |
| Lactate 24 h after reperfusion | 1.3 (1.0–2.3) |
| Peak transaminases—IU/L | |
| ALT | 675 (419–1378) |
| AST | 1130 (722–2517) |
| Primary non‐function b | 1 (1.1%) |
| Early allograft dysfunction c | 33 (35%) |
| Machine perfusion‐early allograft dysfunction d | 13 (14%) |
| Vascular complications | |
| Portal vein thrombosis e | 1 (1.1%) |
| Hepatic artery thrombosis f | 2 (2.2%) |
| Kidney failure requiring CVVH g | 4 (4.3%) |
| Duration of stay—days | |
| In the intensive care unit | 4 (2–7) |
| In the hospital | 19 (14–29) |
| Biliary complications | |
| Non‐anastomotic biliary strictures h | 1 (1.1%) |
| Anastomotic biliary stricture | 3 (3.2%) |
| Biliary leakage i | 4 (4.3%) |
| Postoperative complications j | |
| Clavien‐Dindo 3B | 12 (13%) |
| Clavien‐Dindo 4A | 14 (15%) |
| Clavien‐Dindo 4B | 5 (5.4%) |
| Clavien‐Dindo 5 | 4 (4.3%) |
| Retransplantation within 1 year | 5 (5.4%) |
| Primary non‐function | 1 (1.1%) |
| Hepatic artery thrombosis | 2 (2.2%) |
| Portal vein thrombosis | 1 (1.1%) |
| Multi‐organ failure with secondary liver failure | 1 (1.1%) |
| Patient death within 1 year | 6 (6.5%) |
| Multi‐organ failure | 1 (1.1%) |
| Small‐cell lung carcinoma | 1 (1.1%) |
| Myocardial infarction | 1 (1.1%) |
| Sepsis | 1 (1.1%) |
| Aspergillosis pneumonia | 1 (1.1%) |
| Duodenal perforation with erosive bleeding | 1 (1.1%) |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CVVH, continuous veno‐venous hemofiltration.
Hemodynamic instability after reperfusion defined as post‐reperfusion syndrome with a decrease in mean arterial pressure >30% below baseline, lasting for ≥1 min, within 5 min after reperfusion (Aggarwal criteria 6 ), or as vasoplegia with a fall in mean arterial pressure on reperfusion to <50 mmHg either sustained >30 min and/or requiring >0.15 µg/kg/min norepinephrine, >2 U/h vasopressin, or infusion of epinephrine (significant hypotension resistant to pressors).
Nonlife sustaining graft function leading to graft loss or retransplantation within 7 days after liver transplantation.
Presence of one or more of the following: bilirubin ≥10 mg/dl on postoperation day 7, INR ≥1.6 on postoperative day 7, and ALT or AST >2000 IU/L within the first 7 days (Olthoff criteria).
Presence of 1 or more of the following: bilirubin ≥10 mg/dl on postoperative day 7, INR ≥1.6 on postoperative day 7, lactate ≥2 mmol/L on postoperative day 7 in the absence of vascular complications (mpEAD).
Radiologically or surgically proven thrombosis of the portal vein within 12 month after liver transplantation.
Radiologically or surgically proven thrombosis of the hepatic artery within 12 months after liver transplantation.
Kidney failure defined as (1) increase serum creatinine by ≥0.3 mg/dl within 48 h after transplantation or (2) increase in serum creatinine ≥1.5 times baseline or (3) urine volume <0.5 ml/kg/h for 6 h. Assessed within 30 days after liver transplantation.
Radiological appearance of irregularities and beading dilatation of the intrahepatic bile ducts and/or the presence of cavitations and bile lakes leading to surgical or endoscopic intervention within 12 months after liver transplantation.
Biliary leakage as defined by the International Study Group for Liver Surgery. 24
The complication with the highest grade according to Clavien‐Dindo was scored. Complications were assessed within 30 days after liver transplantation.